Zydus Lifesciences (BOM:532321) Other Financing: ₹0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:532321 Zydus Lifesciences Ltd BOM:532321
93 GF Score
Price ₹1,119.50
GF Value ₹1,222.41
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Zydus Lifesciences Other Financing?

Zydus Lifesciences BOM:532321 +0.13% 93 Other Financing is ₹0 Mil as of Jun. 2026. GuruFocus rates BOM:532321 with a GF Score™ of 93/100 and a GF Value™ of ₹1,222.41 (Fairly Valued). The stock has 3 warning signs investors should review.

Zydus Lifesciences's Other Financing for the three months ended in Jun. 2026 was ₹0 Mil.

Zydus Lifesciences's Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 was ₹0 Mil.

Zydus Lifesciences Other Financing Historical Data

* Premium members only.

The historical data trend for Zydus Lifesciences's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zydus Lifesciences Other Financing Chart

Zydus Lifesciences Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -26.00 0.00 0.00 -294.00 -510.00

Zydus Lifesciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:532321
93GF Score
Zydus Lifesciences Ltd BOM:532321
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zydus Lifesciences Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of ₹0 Mil mean?
Zydus Lifesciences (BOM:532321) has a Other Financing of ₹0 Mil as of Jun. 2026. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zydus Lifesciences and its competitors.
Is Zydus Lifesciences' Other Financing too high?
Zydus Lifesciences' current Other Financing is ₹0 Mil. Overall, Zydus Lifesciences has a GF Score™ of 93/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Zydus Lifesciences' Other Financing compare to ZTS?
Zydus Lifesciences' Other Financing of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Drug Manufacturers company?
A good Other Financing depends on the Drug Manufacturers industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for Zydus Lifesciences and its competitors. Zydus Lifesciences's current Other Financing is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zydus Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Zydus Lifesciences (BOM:532321) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,222.41, compared to a current price of ₹1,119.50 — trading 8.4% below its estimated fair value. The current Other Financing is ₹0 Mil. Zydus Lifesciences' overall GF Score™ is 93/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For Zydus Lifesciences (BOM:532321), the current Other Financing is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Zydus Lifesciences (BOM:532321) Overvalued in 2026?

Based on GuruFocus' analysis, Zydus Lifesciences stock appears to be undervalued. The current stock price of ₹1,119.50 is trading 8.4% below its estimated GF Value™ of ₹1,222.41. GuruFocus considers Zydus Lifesciences to be Fairly Valued.

Key valuation signals for BOM:532321:

  • Other Financing: ₹0 Mil
  • GF Value™: ₹1,222.41 vs. price of ₹1,119.50 (8.4% below fair value)
  • GF Score™: 93/100 with 3 warning signs

No single metric tells the full story. See the BOM:532321 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zydus Lifesciences Business Description

Other Exchanges ZYDUSLIFE:India
Address Scheme No. 63, Sarkhej-Gandhinagar Highway, Zydus Corporate Park, Survey No. 536, Near Vaishnodevi Circle, Khoraj (Gandhinagar), Ahmedabad, GJ, IND, 382481
Zydus Lifesciences Ltd is a specialty and generic drug manufacturing company. It is engaged in the research, development, production, marketing, and distribution of pharmaceutical products. The product portfolio of the company includes Active Pharmaceutical Ingredients (API), human formulations, animal health and veterinary, and consumer health and wellness products. Its products are marketed under brands like Amlodac, Inditel, Pivasta, and others. The company's operating segments are: Pharmaceuticals, which derives key revenue, and Consumer products. Geographically, it generates maximum revenue from the United States, followed by India, and other countries.
93GF Score

Get the complete analysis for BOM:532321

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,119.50
Price
₹1,222.41
GF Value